EVAg

This SARS-CoV-2 strain was isolated from a COVID-19 patient from Slovakia in March 2020. Its complete sequence is deposited on GISAID.org under the accession ID EPI_ISL_417879. The virus is freeze-dried.

This SARS-CoV-2 strain was isolated from a COVID-19 patient from Slovakia in march 2020. Its complete sequence is deposited on GISAID.org under the accesion ID EPI_ISL_417879.

Lyophilized encapsidated RNA for SARS-CoV-2 (2019-nCoV) real time RT-PCR targeting region of the RdRp (IP2/IP4) gene, for 100 Rxns (Target designed by Institut Pasteur: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2) The encapsidated RNA has been stabilized to serve as positive control for extraction and real time RT-PCR. Extraction is mandatory before use in real time RT-PCR. SOPs in the attached pdf. For RUO (Research Use Only)

Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 4x24 rxns) for real time RT-PCR of SARS-CoV-2 (2019-nCoV) in the RdRp (IP4) gene. Primers and Probe sequences designed by Institut Pasteur: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2) SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase For RUO (research use only)

Lyophilized encapsidated RNA for SARS-CoV-2 real time RT-PCR targeting region of the RdRp (IP2/IP4) gene (for 100 Rxns) AND Lyophilized ready-to-use primers and probe (Lyoph-P&P) for real time RT-PCR (96 rxns in the form of 4x24 rnxs). Target, primers and probe designed by Institut Pasteur Paris. SOPs in the attached pdf. Disclaimer: This product does not contain the polymerase

Infectious cell culture supernatant containing Human 2019-nCoV strain 2019-nCoV/Italy-INMI1. This strain is preserved under Viral Storage Medium -80C. To confirm its identity the virus has been completely sequenced.

Infectious cellculture supernatant of human 2019-nCoV

Infectious cell culture supernatant containing SARS-Cov-2 (strain Slovenia/SI-4265/20). This strain is preserved under Viral Storage Medium -80C. To confirm its identity the virus has been completely sequenced.

Infectious cell culture supernatant of human 2019-nCoV

Infectious cell culture supernatant of human 2019-nCoV

The in vitro transcribed RNA is the control for the first-line screening assay termed E gene assay. The SARS-CoV full virus RNA is required to control the two confirmatory assays. Dislaimer: Import permit maybe be needed in your country for the SARS-CoV full virus RNA. If yes, please indicate so in your online enquiry.

In vitro transcribed RNA for Wuhan coronavirus (2019-nCoV) real time (RT-)PCR targeting region of the E gene . Protocol and preliminary evaluation for this assays (Corman/Drosten 2020), as of Jan 13, 2020, available from: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 Ref: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045

Expression plasmid for the Nterminal Domain of the MERS CoV Nucleocapsid coding sequence in fusion with a TRX/6-His tag encoding sequence at its 5'. For expression in E. coli

Recombinant expressed and purified receptor-binding domain (RBD) of SARS-CoV-2 for serological assays. The Protein was expressed in Expi293 cells and purified via Strep-Tactin XT and provided in Elution Buffer ( 100mM Tris-HCl; pH 8.0, 150mM NaCl, 1mM EDTA, 50mM Biotin).

Recombinant expressed and purified receptor-binding domain (RBD) of SARS-CoV-2 for serological assays. The Protein was expressed in Expi293 cells and purified via a HisTag and provided in Elution Buffer (50 mM NaH2PO4, 300 mM NaCl, 0,05% Tween, 250 mM Imidazole, pH 8.0).

C-terminal domain of the SARS-CoV-2 nucleprotein (247-418). Pure recombinant protein produced in E. coli and fused with a Avi tag and a Hexa-Hisitidine tag.

N-terminal domain of the SARS-CoV-2 nucleprotein (1-180). Pure recombinant protein produced in E. coli and fused with a Avi tag and a Hexa-Hisitidine tag.

Middle East respiratory syndrome (MERS) Coronavirus, strain IP/COV/MERS/Hu/France/FRA2

Porcine reproductive and respiratory syndrome virus 1 (PRRSV-1), strain "Cobbelsdorf DZ 2/91", Germany 1991, infectious cell culture supernatant

Porcine reproductive and respiratory syndrome virus 2 (PRRSV-2), strain "USA", Germany 1998, infectious cell culture supernatant

Lyophilized encapsidated RNA for SARS-CoV-2 (2019-nCoV) real time RT-PCR targeting region of the RdRp gene, for 25 Rxns (Target designed by Charité Universitätsmedizin Berlin). The encapsidated RNA has been stabilized to serve as positive control for extraction and real time RT-PCR. Extraction is mandatory before use in real time RT-PCR. SOPs in the attached pdf. For RUO (Research Use Only)

This product represents cDNA material, transcribed with random hexamers from total RNA extracted from the viral stock of SARS-CoV-2 strain Slovakia/SK-BMC5/2020 which is available as a viable virus under Ref-SKU: 006V-03933.

This product represents total RNA extracted from the viral stock of SARS-CoV-2 strain Slovakia/SK-BMC5/2020 which is available as a viable virus under Ref-SKU: 006V-03933.

Lyophilized encapsidated RNA for SARS-CoV-2 (2019-nCoV) real time RT-PCR targeting region of the E gene, for 100 Rxns (Target designed by Charité Universitätsmedizin Berlin ; https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf). The encapsidated RNA has been stabilized to serve as positive control for extraction and real time RT-PCR. Extraction is mandatory before use in real time RT-PCR. SOPs in the attached pdf. For RUO (Research Use Only)

Infectious cell culture supernatant of SARS-CoV-2 from The Netherlands